Výsledky vyhledávání

Akademický článek

Total baseline tumor size predicts survival among patients with advanced small-cell lung cancer receiving chemotherapy plus programmed death-ligand 1 inhibitor as first-line therapy: a multicenter retrospective observational study

Autor: Anna Tanaka, Shuhei Teranishi, Yukihito Kajita, Tomofumi Hirose, Ayami Kaneko, Yu Sairenji, Hidetoshi Kawashima, Kentaro Yumoto, Toshinori Tsukahara, Kenji Miura, Nobuaki Kobayashi, Masaki Yamamoto, Ryuichi Nishihira, Makoto Kudo, Naoki Miyazawa, Masanori Nishikawa, Takeshi Kaneko

Publikováno v: Frontiers in Oncology, Vol 14 (2024)

IntroductionTotal baseline tumor size (BTS) is a prognostic factor for programmed death 1 and programmed death-ligand 1 (PD-L1) inhibitor treatments. However, the prognostic value of total BTS for patients with small-cell lung cancer (SCLC) who recei

Externí odkaz: https://doaj.org/article/99db2f11197c43fb830593424fcc72e2

Zobrazit plný text záznamu

Akademický článek

Real‐world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non‐small cell lung cancer

Publikováno v: Thoracic Cancer, Vol 15, Iss 15, Pp 1208-1217 (2024)

Abstract Background For advanced non‐small cell lung cancer (NSCLC), combination therapies including a PD‐1 inhibitor plus chemotherapy or a PD‐1 inhibitor, CTLA‐4 inhibitor, and chemotherapy are standard first‐line options. However, data d

Externí odkaz: https://doaj.org/article/a735d5e5686648739b1e27925239e9be

Zobrazit plný text záznamu

Plný text ve formátu HTML

Asymptomatic COVID-19 Re-infection in a Japanese Male by Elevated Half-Maximal Inhibitory Concentration (IC50) of Neutralizing Antibodies

Autor: Mari Terada, Satoshi Kutsuna, Mugen Ujiie, Kenji Maeda, Makoto Inada, Akihiro Matsunaga, Masahiro Ishikane, Hiroaki Mitsuya, Yu Sairenji, Kiyoto Tsuchiya, Noriko Kinoshita, Norio Ohmagari, Kenji Miura, Yukihito Ishizaka

Publikováno v: Journal of Infection and Chemotherapy

Introduction “Re-infection” with COVID-19 is a growing concern; re-infection cases have reported worldwide. However, the clinical characteristics of SARS-CoV-2 re-infection, including the levels and role of anti-SARS-CoV-2 Spike protein IgG antib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f242c6674c8c3730a2ad228c2154315f
http://europepmc.org/articles/PMC8064832

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání